Narrated presentation of results available on
ProMIS website
TSX: PMN
TORONTO and CAMBRIDGE, MA, Oct. 17,
2017 /PRNewswire/ - ProMIS Neurosciences, Inc., a
biotechnology company focused on the discovery and development of
precision treatments for neurodegenerative diseases, today
announced that its lead product candidate for Alzheimer's disease,
PMN310, showed the desired binding profile of selectively targeting
amyloid beta oligomers in a preclinical study directly comparing
PMN310 to other amyloid beta-directed antibodies for
Alzheimer's disease (AD).
A narrated presentation of these results is available on the
ProMIS Neurosciences website at: http://bit.ly/2gp8S4t
Commenting on these results, ProMIS
President and CEO, Elliot
Goldstein, MD, stated: "We are pleased to confirm the
selective binding of PMN310 to amyloid beta oligomers, a root cause
of Alzheimer's disease. Results of prior clinical studies with
other amyloid beta antibody therapeutics clearly showed that
antibodies targeting amyloid beta monomer have consistently been
ineffective, while those targeting amyloid beta fibrils, the main
component of plaque, are associated with a dose limiting toxicity
of brain swelling. Taken together, results of prior clinical trials
indicate the best in class target product profile is selective
binding of toxic amyloid beta oligomers."
The binding profile of PMN310 was compared to that of other
candidate antibody therapeutics for AD in a preclinical study using
the "dot blot" technique. Results of the study showed that PMN310
selectively binds amyloid beta oligomers (AbO), with virtually no
binding to the other forms of amyloid beta. By comparison,
solanezumab (Eli Lilly) showed binding mainly to Ab monomers;
bapineuzumab (Johnson & Johnson/Pfizer, discontinued) showed
binding to all forms of Ab (monomers, fibrils, oligomers); and
aducanumab (Biogen) showed preferential binding to fibrils and
oligomers.
Dot blotting is a method of applying (dotting) proteins, such as
Ab monomers, fibrils and oligomers, directly onto a membrane or
other support. Samples of the antibody to be evaluated are then
applied and the binding pattern to the various forms of amyloid
beta can be observed.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a Toronto Stock Exchange listed biotech
company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company's
mission is to discover and develop precision medicine therapeutics
for effective treatment of neurodegenerative diseases, in
particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is
based on the use of two, complementary techniques. The Company
applies its thermodynamic, computational discovery
platform—ProMIS™ and Collective Coordinates — to predict
novel targets known as Disease Specific Epitopes (DSEs) on the
molecular surface of misfolded proteins. Using this unique
"precision medicine" approach, ProMIS Neurosciences is developing
novel antibody therapeutics and specific companion diagnostics for
Alzheimer's disease and ALS.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release may contain certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information please consult the Company's website
at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
SOURCE ProMIS Neurosciences Inc.